AR096684A1 - Compuestos para tratar atrofia muscular espinal - Google Patents
Compuestos para tratar atrofia muscular espinalInfo
- Publication number
- AR096684A1 AR096684A1 ARP140102349A ARP140102349A AR096684A1 AR 096684 A1 AR096684 A1 AR 096684A1 AR P140102349 A ARP140102349 A AR P140102349A AR P140102349 A ARP140102349 A AR P140102349A AR 096684 A1 AR096684 A1 AR 096684A1
- Authority
- AR
- Argentina
- Prior art keywords
- alkyl
- haloalkyl
- halo
- haloalkoxy
- alkoxy
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 2
- 206010028289 Muscle atrophy Diseases 0.000 title 1
- 230000020763 muscle atrophy Effects 0.000 title 1
- 201000000585 muscular atrophy Diseases 0.000 title 1
- 125000000217 alkyl group Chemical group 0.000 abstract 6
- 125000001188 haloalkyl group Chemical group 0.000 abstract 5
- 125000005843 halogen group Chemical group 0.000 abstract 5
- 125000003545 alkoxy group Chemical group 0.000 abstract 4
- 125000004438 haloalkoxy group Chemical group 0.000 abstract 4
- 229910052739 hydrogen Inorganic materials 0.000 abstract 4
- 239000001257 hydrogen Substances 0.000 abstract 4
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 4
- 125000006272 (C3-C7) cycloalkyl group Chemical group 0.000 abstract 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 abstract 1
- 125000002947 alkylene group Chemical group 0.000 abstract 1
- 125000004429 atom Chemical group 0.000 abstract 1
- 125000002619 bicyclic group Chemical group 0.000 abstract 1
- 229910052799 carbon Inorganic materials 0.000 abstract 1
- 125000004093 cyano group Chemical group *C#N 0.000 abstract 1
- 125000005842 heteroatom Chemical group 0.000 abstract 1
- 125000000592 heterocycloalkyl group Chemical group 0.000 abstract 1
- 125000002950 monocyclic group Chemical group 0.000 abstract 1
- 125000004433 nitrogen atom Chemical group N* 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 229920006395 saturated elastomer Polymers 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
- C07D263/52—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings condensed with carbocyclic rings or ring systems
- C07D263/54—Benzoxazoles; Hydrogenated benzoxazoles
- C07D263/56—Benzoxazoles; Hydrogenated benzoxazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/10—Spiro-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Epidemiology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Plural Heterocyclic Compounds (AREA)
- Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Abstract
Reivindicación 1: Compuestos de fórmula (1) en la que X es N o CR³; Y es N o CR⁴; con la condición de que X e Y no son ambos N; A es un heteroarilo bicíclico de 9 miembros que comprende dos o tres heteroátomos seleccionados independientemente entre N u O, en la que A puede estar opcionalmente sustituido con uno, dos o tres R⁵; B es un heterocicloalquilo de 4 a 9 miembros mono o bicíclico saturado o parcialmente insaturado que comprende uno o dos átomos de nitrógeno en el anillo, siendo carbono los demás átomos en el anillo, en la que B puede estar opcionalmente sustituido con uno, dos o tres R⁶; R¹ es hidrógeno, halo, alquilo C₁₋₇, haloalquilo C₁₋₇, alcoxi C₁₋₇ o haloalcoxi C₁₋₇; R² es hidrógeno, halo, alquilo C₁₋₇ haloalquilo C₁₋₇, alcoxi C₁₋₇ o haloalcoxi C₁₋₇; R³ es hidrógeno, halo, alquilo C₁₋₇ haloalquilo C₁₋₇, alcoxi C₁₋₇ o haloalcoxi C₁₋₇; R⁴ es hidrógeno, halo, alquilo C₁₋₇, haloalquilo C₁₋₇ alcoxi C₁₋₇ o haloalcoxi C₁₋₇; cada R⁵ se selecciona independientemente entre halo, ciano, alquilo C₁₋₇, haloalquilo C₁₋₇ o cicloalquilo C₃₋₇; cada R⁶ se selecciona independientemente entre alquilo C₁₋₇ o dos R⁶ juntos forman un alquileno C₂₋₇; y sales farmacéuticamente aceptables de los mismos.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP13173487 | 2013-06-25 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR096684A1 true AR096684A1 (es) | 2016-01-27 |
Family
ID=48669815
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP140102349A AR096684A1 (es) | 2013-06-25 | 2014-06-23 | Compuestos para tratar atrofia muscular espinal |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US20160145270A1 (es) |
| EP (1) | EP3013345B1 (es) |
| JP (1) | JP6492071B2 (es) |
| KR (1) | KR102314290B1 (es) |
| CN (1) | CN105358151B (es) |
| AR (1) | AR096684A1 (es) |
| BR (1) | BR112015030288B1 (es) |
| CA (1) | CA2913785C (es) |
| HK (1) | HK1215399A1 (es) |
| MX (1) | MX363456B (es) |
| RU (1) | RU2673542C2 (es) |
| TW (1) | TW201542543A (es) |
| WO (1) | WO2014209841A2 (es) |
Families Citing this family (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3035935B1 (en) | 2013-08-19 | 2020-03-11 | F. Hoffmann-La Roche AG | Compounds for use in the prophylaxis and treatment of cancer |
| GB201410693D0 (en) | 2014-06-16 | 2014-07-30 | Univ Southampton | Splicing modulation |
| JP6675334B2 (ja) | 2014-06-25 | 2020-04-01 | エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ | 脊髄性筋萎縮症を処置するためのイミダゾ［１，２−ａ］ピラジン−１−イルベンズアミド化合物 |
| SG11201702682PA (en) | 2014-10-03 | 2017-04-27 | Cold Spring Harbor Lab | Targeted augmentation of nuclear gene output |
| WO2016161572A1 (en) | 2015-04-08 | 2016-10-13 | Merck Sharp & Dohme Corp. | TrkA KINASE INHIBITORS, COMPOSITIONS AND METHODS THEREOF |
| AU2016334804B2 (en) | 2015-10-09 | 2022-03-31 | University Of Southampton | Modulation of gene expression and screening for deregulated protein expression |
| EA036399B1 (ru) | 2015-11-12 | 2020-11-06 | Ф. Хоффманн-Ля Рош Аг | Композиции для лечения спинальной мышечной атрофии |
| CN108137579B (zh) | 2015-12-10 | 2022-01-07 | 豪夫迈·罗氏有限公司 | 桥连哌啶衍生物 |
| LT3386511T (lt) | 2015-12-10 | 2021-08-25 | Ptc Therapeutics, Inc. | Hantingtono ligos gydymo būdai |
| KR102604132B1 (ko) | 2015-12-14 | 2023-11-17 | 콜드스프링하버러보러토리 | 상염색체 우성 정신 지체 5 및 드라베 증후군의 치료를 위한 안티센스 올리고머 |
| US11096956B2 (en) | 2015-12-14 | 2021-08-24 | Stoke Therapeutics, Inc. | Antisense oligomers and uses thereof |
| IL300875A (en) | 2017-06-05 | 2023-04-01 | Ptc Therapeutics Inc | Compounds for the treatment of Huntington's disease |
| CA3067591A1 (en) | 2017-06-28 | 2019-01-03 | Ptc Therapeutics, Inc. | Methods for treating huntington's disease |
| MX2019015580A (es) | 2017-06-28 | 2020-07-28 | Ptc Therapeutics Inc | Metodos para tratar la enfermedad de huntington. |
| GB2579747B8 (en) | 2017-08-04 | 2022-10-05 | Skyhawk Therapeutics Inc | Methods and compositions for modulating splicing |
| BR112020003591A2 (pt) | 2017-08-25 | 2020-09-01 | Stoke Therapeutics, Inc. | oligômeros anti-senso para o tratamento de condições e doenças |
| US20210268667A1 (en) | 2017-10-23 | 2021-09-02 | Stoke Therapeutics, Inc. | Antisense oligomers for treatment of non-sense mediated rna decay based conditions and diseases |
| KR20210005559A (ko) | 2018-03-27 | 2021-01-14 | 피티씨 테라퓨틱스, 인크. | 헌팅턴병 치료 화합물 |
| CA3099280A1 (en) | 2018-05-04 | 2019-11-07 | Stoke Therapeutics, Inc. | Methods and compositions for treatment of cholesteryl ester storage disease |
| RS65727B1 (sr) | 2018-06-27 | 2024-08-30 | Ptc Therapeutics Inc | Heterociklična i heteroaril jedinjenja za lečenje hantingtonove bolesti |
| CA3105174A1 (en) | 2018-06-27 | 2020-01-02 | Reborna Biosciences, Inc. | Prophylactic or therapeutic agent for spinal muscular atrophy |
| CN112805280B (zh) | 2018-06-27 | 2024-12-06 | Ptc医疗公司 | 用于治疗亨廷顿氏病的杂芳基化合物 |
| WO2020005882A1 (en) | 2018-06-27 | 2020-01-02 | Ptc Therapeutics, Inc. | Heteroaryl compounds for treating huntington's disease |
| PE20211693A1 (es) | 2018-11-02 | 2021-09-01 | Merck Sharp & Dohme | 2- amino-n-heteroaril-nicotinamidas como inhibidores de nav1.8 |
| JP7576552B2 (ja) | 2019-01-18 | 2024-10-31 | バイオジェン・エムエイ・インコーポレイテッド | イミダゾ［１，２－ａ］ピリジニル誘導体及び疾患の処置におけるその使用 |
| JP7603592B2 (ja) | 2019-02-05 | 2024-12-20 | スカイホーク・セラピューティクス・インコーポレーテッド | スプライシングを調節するための方法および組成物 |
| EP3920928A4 (en) | 2019-02-06 | 2022-09-28 | Skyhawk Therapeutics, Inc. | METHODS AND COMPOSITIONS FOR MODULATION OF SPLICING |
| KR20210131374A (ko) | 2019-02-25 | 2021-11-02 | 베이징 이노케어 파마 테크 씨오., 엘티디. | 6-(1-아크릴로일피페리딘-4-일)-2-(4-페녹시페닐) 니코틴아미드의 제조 방법 |
| WO2021007378A1 (en) | 2019-07-11 | 2021-01-14 | Ptc Therapeutics, Inc. | Compounds for use in treating huntington's disease |
| AU2021270720A1 (en) | 2020-05-11 | 2022-12-08 | Stoke Therapeutics, Inc. | OPA1 antisense oligomers for treatment of conditions and diseases |
| KR20230028269A (ko) | 2020-05-13 | 2023-02-28 | 씨에이치디아이 파운데이션, 인코포레이티드 | 헌팅턴병을 치료하기 위한 htt 조절제 |
| WO2022169230A1 (ko) * | 2021-02-03 | 2022-08-11 | 단국대학교 천안캠퍼스 산학협력단 | 6-메톡시니코틴아미드를 유효성분으로 포함하는 근감소증의 예방 또는 치료용 조성물 |
| WO2023102231A1 (en) * | 2021-12-03 | 2023-06-08 | Rgenta Therapeutics, Inc. | 5-pyrimidinecarboxamide derivatives and methods of using the same |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE9801526D0 (sv) * | 1998-04-29 | 1998-04-29 | Astra Ab | New compounds |
| ES2359836T3 (es) * | 2004-04-23 | 2011-05-27 | Bristol-Myers Squibb Company | Heterociclos monociclicos como inhibidores de quinasa. |
| WO2006101455A1 (en) | 2005-03-21 | 2006-09-28 | S*Bio Pte Ltd | Imidazo[1,2-a]pyridine derivatives: preparation and pharmaceutical applications |
| US7666880B2 (en) * | 2005-03-21 | 2010-02-23 | S*Bio Pte Ltd. | Imidazo[1,2-A]pyridine derivatives: preparation and pharmaceutical applications |
| JP2009514859A (ja) * | 2005-11-03 | 2009-04-09 | メルク エンド カムパニー インコーポレーテッド | 置換ニコチンアミド化合物 |
| EP2215074B1 (en) * | 2007-09-27 | 2014-02-19 | The United States of America, as Represented by the Secretary, Department of Health and Human Services | Isoindoline compounds for the treatment of spinal muscular atrophy and other uses |
| US8633019B2 (en) * | 2008-05-27 | 2014-01-21 | Ptc Therapeutics, Inc. | Methods for treating spinal muscular atrophy |
| JP5502077B2 (ja) * | 2008-06-05 | 2014-05-28 | グラクソ グループ リミテッド | 新規な化合物 |
| WO2010019236A1 (en) * | 2008-08-13 | 2010-02-18 | Ptc Therapeutics, Inc | Methods for treating spinal muscular atrophy |
| UY32138A (es) * | 2008-09-25 | 2010-04-30 | Boehringer Ingelheim Int | Amidas sustituidas del ácido 2-(2,6-dicloro-fenilamino)-6-fluoro-1-metil-1h-bencimidazol-5-carboxílico y sus sales farmacéuticamente aceptables |
| WO2012142459A1 (en) * | 2011-04-14 | 2012-10-18 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Isoindoline compounds for the treatment of spinal muscular atrophy and other uses |
-
2014
- 2014-06-23 US US14/899,397 patent/US20160145270A1/en not_active Abandoned
- 2014-06-23 BR BR112015030288-2A patent/BR112015030288B1/pt active IP Right Grant
- 2014-06-23 AR ARP140102349A patent/AR096684A1/es unknown
- 2014-06-23 KR KR1020157036344A patent/KR102314290B1/ko active IP Right Grant
- 2014-06-23 MX MX2015017345A patent/MX363456B/es unknown
- 2014-06-23 EP EP14816651.5A patent/EP3013345B1/en active Active
- 2014-06-23 RU RU2015154676A patent/RU2673542C2/ru active
- 2014-06-23 CA CA2913785A patent/CA2913785C/en active Active
- 2014-06-23 CN CN201480035676.2A patent/CN105358151B/zh active Active
- 2014-06-23 WO PCT/US2014/043577 patent/WO2014209841A2/en active Application Filing
- 2014-06-23 JP JP2016523822A patent/JP6492071B2/ja active Active
- 2014-06-24 TW TW103121679A patent/TW201542543A/zh unknown
-
2016
- 2016-03-24 HK HK16103480.3A patent/HK1215399A1/zh unknown
-
2018
- 2018-04-09 US US15/948,444 patent/US10501482B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| WO2014209841A3 (en) | 2015-10-29 |
| MX2015017345A (es) | 2016-08-03 |
| CA2913785C (en) | 2021-08-31 |
| EP3013345A2 (en) | 2016-05-04 |
| BR112015030288A2 (es) | 2017-08-22 |
| US10501482B2 (en) | 2019-12-10 |
| CN105358151B (zh) | 2019-04-12 |
| JP2016530231A (ja) | 2016-09-29 |
| RU2015154676A (ru) | 2017-07-28 |
| EP3013345A4 (en) | 2016-11-30 |
| KR20160022312A (ko) | 2016-02-29 |
| US20180222925A1 (en) | 2018-08-09 |
| HK1215399A1 (zh) | 2016-08-26 |
| RU2015154676A3 (es) | 2018-03-15 |
| US20160145270A1 (en) | 2016-05-26 |
| CA2913785A1 (en) | 2014-12-31 |
| WO2014209841A2 (en) | 2014-12-31 |
| KR102314290B1 (ko) | 2021-10-21 |
| BR112015030288B1 (pt) | 2022-10-18 |
| RU2673542C2 (ru) | 2018-11-28 |
| TW201542543A (zh) | 2015-11-16 |
| JP6492071B2 (ja) | 2019-03-27 |
| CN105358151A (zh) | 2016-02-24 |
| EP3013345B1 (en) | 2017-11-22 |
| MX363456B (es) | 2019-03-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR096684A1 (es) | Compuestos para tratar atrofia muscular espinal | |
| AR100809A1 (es) | Inhibidores de fosfatidilinositol 3-quinasa | |
| CY1120635T1 (el) | Βενζαμιδια αμινοετεροαρυλιου ως αναστολεις κινασης | |
| AR099379A1 (es) | Compuestos tricíclicos como agentes antineoplásicos | |
| AR100442A1 (es) | Derivados de pirido[1,2-a]pirimidin-4-ona para tratar atrofia muscular espinal | |
| AR104326A1 (es) | Compuestos nucleósidos 5-sustituidos | |
| GT201200346A (es) | Derivados de imidazopiridina, su procedimiento de preparaciòn y su aplicaciòn en terapèutica | |
| AR106472A1 (es) | Inhibidores de acc y usos de los mismos | |
| AR099177A1 (es) | Determinadas (2s)-n-[(1s)-1-ciano-2-feniletil]-1,4-oxazepan-2-carboxamidas como inhibidores de dipeptidil peptidasa 1 | |
| AR097866A1 (es) | Derivados de 4-azaindol | |
| AR094668A1 (es) | Amidas como moduladores de canales de sodio | |
| AR089671A1 (es) | 1,4-dihidropirimidinas 4,4-disustituidas y su uso como medicamentos para el tratamiento de la hepatitis b | |
| AR099415A1 (es) | Benzoilfenil-formamidinas con actividad fungicida, sus composiciones agronómicas y su uso para el control de hongos fitopatogénicos de cultivos agrarios | |
| NI201200191A (es) | Derivados de indolizina, su procedimiento de preparación y su aplicación en terapéutica | |
| AR106053A1 (es) | Compuestos imidazo[4,5-c]quinolin-2-ona y su uso para el tratamiento del cáncer | |
| MA38982A1 (fr) | Nouvel octahydro-cyclobuta [1,2-c; 3,4-c'] dipyrrol-2-yl | |
| AR106100A1 (es) | Compuestos bicíclicos como inhibidores duales atx / ca | |
| EA201390163A1 (ru) | Гетеробициклические производные в качетстве ингибиторов hcv | |
| AR094702A1 (es) | Compuestos de azabencimidazol | |
| AR101051A1 (es) | Compuestos no esteroideos inhibidores de cyp17 / antiandrógenos | |
| CL2019001694A1 (es) | Compuestos de pirazolopirimidina y métodos de uso de los mismos. | |
| AR092749A1 (es) | Compuestos farmaceuticos | |
| CR20160070A (es) | Compuestos de triazolopiridina, composiciones y métodos de uso de los mismos | |
| AR096153A1 (es) | Derivados de pirrolo[2,3-d]pirimidina | |
| EA201791671A1 (ru) | 4-замещенные соединения бензоксаборола и их применение |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |